Clinical trials: Coronary Stent Occlusion
Coronary Artery Disease
Fractional Flow Reserve-guided Provisional Side Branch Intervention
Study purpose: To evaluate fractional flow reserve-guided side branch intervention strategy Method: Provisional side branch intervention if jailed side branch FFR<0.75
- Trial name
- NCT00351780
- Testing
- FFR measurement, side branch angioplasty
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Seoul National University Hospital
Coronary Heart Disease
Recovery of Left Ventricular Function in Chronic Total Occluded Coronary Arteries
The study is a randomised comparison of recanalisation of chronic occluded coronary arteries with implantation of Sirolimus eluting stents and medical therapy.
- Trial name
- REVASC (NCT01924962)
- Testing
- revascularisation
- Where
- Germany
- Volunteers
- 205 people
- Sponsor
- University Heart Center Freiburg - Bad Krozingen
Coronary Artery Disease
Synergy Between Stent and Drugs to Avoid Ischemic Recurrences After Percutaneous Coronary Intervention
The duration of dual antiplatelet treatment (i.e. asprin and clopidogrel) after drug-eluting stent implantation is highly debated.
- Trial name
- PRODIGY (NCT00611286)
- Testing
- clopidogrel treatment after bare metal stent implantation, clopidogrel after zotarolimus-eluting stent implantation, clopidogrel after paclitaxel-eluting stent implantation
- Where
- Italy
- Volunteers
- 1,700 people
- Sponsor
- Marco Valgimigli
Coronary Artery Disease
OPTIMIZE-APT: Tailored Versus Conventional Antiplatelet Therapy After Intravascular Imaging-guided Drug-eluting Stent Implantation
Objectives: To assess the safety of tailored antiplatelet therapy (short DAPT followed by P2Y12 inhibitor alone strategy) in patients who received optimized DES implantation guided by intravascular imaging (IVUS or OCT)…
- Trial name
- OPTIMIZE-APT (NCT05418556)
- Testing
- aspirin
- Where
- 33 sites in South Korea
- Volunteers
- 3,944 people
- Sponsor
- Asan Medical Center
Coronary Artery Disease
Study to Test the Efficacy and Safety of Drug Eluting vs. Bare-Metal Stents for Saphenous Vein Graft Interventions
Prospective multicenter controlled randomized trial to compare the safety and efficacy of drug eluting vs. bare metal stents in percutaneous coronary interventions of saphenous vein grafts.
- Trial name
- BASKET-SAVAGE (NCT00595647)
- Testing
- Drug eluting stent, Bare metal stent
- Where
- 5 sites in Denmark, Germany and 1 more
- Volunteers
- 162 people
- Sponsor
- University Hospital, Basel, Switzerland
Ischaemic Heart Disease
BIOFREEDOM Stent Versus ORSIRO Stent: SORT OUT IX
The aim of the Danish Organization for Randomized Trials with Clinical Outcome (SORT OUT) is to compare the safety and efficacy of the polymer-free Biolimus-eluting BIOFREEDOM stent with a biodegradable-polymer Sirolimus-eluting…
- Trial name
- SORT OUT IX (NCT02623140)
- Testing
- Biofreedom, Orsiro
- Where
- Denmark
- Volunteers
- 3,150 people
- Sponsor
- Odense University Hospital
Chronic Kidney Diseases, Coronary Artery Disease
Clinical Impact of Orsiro™ Stent in Patient With Chronic Kidney Disease
Orsiro™ or Orsiro_Mission™ stents have the biodegradable polymer and the thinnest stent strut (60㎛) in commercially available stents, which could minimize chronic inflammation and incomplete endothelialization.
- Trial name
- OKAY (NCT06475625)
- Testing
- Percutaneous coronary intervention, Orsiro™ or Orsiro_Mission™ stent
- Where
- South Korea
- Volunteers
- 3,113 people
- Sponsor
- The Catholic University of Korea
Coronary Artery Disease
Two-stent vs Provisional Stenting Techniques for Patients With Complex Coronary Bifurcation Lesions
The purpose of this study is to establish the optimal strategy for stenting in coronary bifurcation lesion.
- Trial name
- DEFINITION-II (NCT02284750)
- Testing
- Percutaneous coronary intervention
- Where
- China
- Volunteers
- 660 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Coronary Artery Disease
A Randomized Controlled Comparison Between One Versus More Than Six Months of Dual Antiplatelet Therapy After Biolimus A9-eluting Stent Implantation
DES are preferred over BMS for most patients, however prolonged dual antiplatelet therapy is required for patients treated with DES for prevention of late or very late stent thrombosis. which increases a risk of major bleeding.
- Trial name
- NCT02513810
- Testing
- BioFreedom with 1 month DAPT, BioMatrix or Ultimaster with 6 to 12 months DAPT
- Where
- South Korea
- Volunteers
- 3,020 people
- Sponsor
- Yonsei University
Coronary Artery Bypass, Arteriosclerosis
The SOS (Stenting Of Saphenous Vein Grafts) Trial
The main purpose of this study is to determine whether implantation of a paclitaxel-eluting stent (Taxus™) in saphenous vein graft lesions will reduce the incidence of in-stent restenosis after 12 months when compared to a…
- Trial name
- NCT00247208
- Testing
- Taxus polymer-based paclitaxel-eluting stent, Express 2 bare metal stent
- Where
- 5 sites in United States, Greece
- Volunteers
- 80 people
- Sponsor
- North Texas Veterans Healthcare System
Coronary Artery Disease
Smart Angioplasty Research Team-Optimal Strategy for Side Branch Stenting in Coronary Bifurcation Lesion With Drug-Coated Balloon
A prospective, multi-center, open-label, randomized controlled, superiority trial. The aim of the study is to compare clinical outcomes between upfront 2-stenting strategy versus upfront drug-coated balloon (DCB)-based hybrid…
- Trial name
- SMART-DCB (NCT07019350)
- Testing
- Upfront DCB-based hybrid strategy, Upfront 2-stenting strategy
- Where
- 3 sites in South Korea
- Volunteers
- 520 people
- Sponsor
- Samsung Medical Center
Elevated Lipoprotein(a) Level, Coronary Artery Disease
24 Versus 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stent in Patients With Elevated Lipoprotein(a) Levels: A Prospective, Multicenter, Double-Blind, Placebo-Controlled Randomized Trial
1. Main objective Among patients with elevated Lp(a) levels (>30mg/dL) who did not experience cardiovascular events or BARC type 2, 3, or 5 bleeding within 12 months after PCI and DES implantation, was it possible to reduce the…
- Conditions
- Elevated Lipoprotein(a) Level, Coronary Artery Disease, Drug-Eluting Stent, Dual Antiplatelet Therapy
- Trial name
- DAPT-Lp(a) (NCT06014060)
- Testing
- 24 Months DAPT, 12 Months DAPT
- Where
- China
- Volunteers
- 3,300 people
- Sponsor
- China National Center for Cardiovascular Diseases
Coronary Artery Disease
The E-SERIES Registry for Supralimus® Coronary Stent for the Treatment of Unselected Patients With Coronary Lesions
E-SERIES Registry evaluate the procedural and clinical outcomes of the Supralimus® SES in the treatment of unselected, high risk patients having coronary Artery blockage in the real world clinical practice.
- Trial name
- NCT01368627
- Testing
- Supralimus® Sirolimus-Eluting Coronary Stent
- Where
- 7 sites in Brazil
- Volunteers
- 1,274 people
- Sponsor
- Sahajanand Medical Technologies Limited
Coronary Stenosis, Coronary Artery Disease
Long-term Follow-up of a Randomized Comparison of Percutaneous Coronary Intervention Versus Coronary Artery Bypass Surgery
This is a long-term follow-up of a completed clinical trial which compared percutaneous coronary intervention (PCI) using sirolimus-eluting stents and coronary artery bypass grafting (CABG) in patients with unprotected left main…
- Trial name
- NCT05963620
- Testing
- percutaneous coronary intervention vs bypass graft surgery
- Where
- 4 sites in Germany
- Volunteers
- 201 people
- Sponsor
- Heart Center Leipzig - University Hospital
Coronary Artery Disease
Abrupt Versus Tapered Interruption of Chronic Clopidogrel Therapy After DES Implantation
The hypothesis to be tested is that gradual clopidogrel therapy cessation is associated with a superior clinical outcome compared with abrupt cessation (superiority hypothesis).
- Trial name
- ISAR-CAUTION (NCT00640679)
- Testing
- Abrupt Clopidogrel Interruption, Clopidogrel Tapering
- Where
- 2 sites in Germany
- Volunteers
- 782 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Coronary Disease, Coronary Artery Disease
SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System
Prospective, randomized, active-control, single blind, parallel two-arm multi-center clinical trial comparing XIENCE V® Everolimus Eluting Coronary Stent System to the approved commercially available active control TAXUS™…
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- SPIRIT II (NCT00180310)
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent, TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
- Where
- 32 sites in Austria, Belgium and 11 more
- Volunteers
- 300 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 4
This study is multi-center, open label, two-by-two factorial, randomized, noninferiority trial to compare the efficacy and safety of polymer-free cobalt-chromium thin drug-coated stents (BioFreedom Ultra) with biodegradable…
- Trial name
- SMART-CHOICE4 (NCT05066789)
- Testing
- Type of stent, Duration of DAPT
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Samsung Medical Center
Coronary Artery Disease
Non-inferiority Trial to Assess the Safety and Performance of the Evolution Coronary Stent
The purpose of the EVOLVE Trial is to assess the safety and performance of the everolimus-eluting Evolution stent for the treatment of a de novo atherosclerotic lesion of up to 28 mm in length in a native coronary artery 2.25 mm…
- Trial name
- Evolve (NCT01135225)
- Testing
- PROMUS(TM) Element (TM) Stent System, Evolution Stent System
- Where
- 29 sites in Australia, Belgium and 7 more
- Volunteers
- 291 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease, Antineoplastic Agents
Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System Clinical Study
The Bioheart Randomized Controlled Trial is a prospective multicentred paralleled study, which will enroll 430 patients and randomized 1:1 to study group and control group.
- Trial name
- NCT03284255
- Testing
- study group, control group
- Where
- 25 sites in China
- Volunteers
- 431 people
- Sponsor
- Shanghai Bio-heart Biological Technology Co., Ltd.
Angina Pectoris, Acute Coronary Syndrome
Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19
Management of known patients with cardiovascular disease (in particular the whole spectrum of atherosclerotic ischaemic coronary artery disease, essential hypertension under treatment, and also patients with chronic heart failure…
- Conditions
- Angina Pectoris, Acute Coronary Syndrome, Coronary Syndrome, Coronary Artery Disease
- Trial name
- eCardioCovid19 (NCT04325867)
- Testing
- Tele-medicine platform
- Where
- 2 sites in Romania
- Volunteers
- 200 people
- Sponsor
- Professor Adrian Covic